FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897449632> ?p ?o ?g. }

• W2897449632 endingPage "272" @default.
• W2897449632 startingPage "265" @default.
• W2897449632 abstract "Objectives Contrasting other EGFR mutations (EGFRm) in lung adenocarcinomas, insertions in exon 20 (exon20ins) are generally associated with resistance to targeted therapy, limiting therapeutic options and impoverishing the prognosis compared to other EGFRm. We sought to extensively characterize exon20ins from a large cohort of lung adenocarcinomas in Hispanic patients. Materials and methods This was a region-wide, observational longitudinal cohort study to evaluate characteristics and outcomes of patients with exon20ins in lung adenocarcinoma, based on a secondary analysis of electronic records from the Geno1.2-CLICaP Platform and extended genotype testing. Patients from six Latin-American countries were included (Argentina, Colombia, Costa Rica, Ecuador, Panama, and Mexico). Data obtained included the molecular spectrum (extended genotyping for mutations in BRAF, NRAS, PIK3CA, Her2 and MEK1, as well as for EGFR amplification, ALK and PD-L1 protein expression), clinic-pathologic characteristics, prevalence and outcomes to therapeutic approach. Results and conclusions 4.005 patients diagnosed with stage III/IV lung adenocarcinoma from 2011 to 2016 were initially screened. Among these, 88 patients had a confirmed exon20 in. and were included; median age was 66-years, 62.5% were females, 64% were never smokers and 39% presented with brain metastases. The H773insH variant was the most frequent, making up 21.6% of cases. A common EGFRm was concomitantly found in 36.4% (del19/L858R), and 8% (G719X/L861Q/S768I) of cases. Five cases had additional mutations in PI3K, KRAS and MEK1, 26% had EGFR amplification and 81.7% had PD-L1 expression 1–50%. Overall response rate to first-line therapy was 28% and overall survival was 16.4 months. Prognosis was positively influenced by the concomitant presence of common EGFRm and response to first-line. Our results suggest that patients with EGFR exon20ins have similar clinical characteristics to those with common EGFRm but a poorer prognosis. Last, the mean PD-L1 expression in this population seems higher than for patients with common EGFRm." @default.
• W2897449632 created "2018-10-26" @default.
• W2897449632 creator A5000631349 @default.
• W2897449632 creator A5001634894 @default.
• W2897449632 creator A5014453416 @default.
• W2897449632 creator A5016678816 @default.
• W2897449632 creator A5021231793 @default.
• W2897449632 creator A5021282809 @default.
• W2897449632 creator A5022841989 @default.
• W2897449632 creator A5026742077 @default.
• W2897449632 creator A5034618792 @default.
• W2897449632 creator A5035063101 @default.
• W2897449632 creator A5038974897 @default.
• W2897449632 creator A5040362672 @default.
• W2897449632 creator A5044095460 @default.
• W2897449632 creator A5044612760 @default.
• W2897449632 creator A5044887899 @default.
• W2897449632 creator A5047294452 @default.
• W2897449632 creator A5048183782 @default.
• W2897449632 creator A5050965701 @default.
• W2897449632 creator A5057297789 @default.
• W2897449632 creator A5058117531 @default.
• W2897449632 creator A5059846027 @default.
• W2897449632 creator A5063256236 @default.
• W2897449632 creator A5063353819 @default.
• W2897449632 creator A5065352968 @default.
• W2897449632 creator A5066679669 @default.
• W2897449632 creator A5066965894 @default.
• W2897449632 creator A5071381310 @default.
• W2897449632 creator A5073629477 @default.
• W2897449632 creator A5080166013 @default.
• W2897449632 date "2018-11-01" @default.
• W2897449632 modified "2023-10-17" @default.
• W2897449632 title "EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP)" @default.
• W2897449632 cites W1566300951 @default.
• W2897449632 cites W1973392642 @default.
• W2897449632 cites W1976422747 @default.
• W2897449632 cites W1984005163 @default.
• W2897449632 cites W2039427024 @default.
• W2897449632 cites W2040178944 @default.
• W2897449632 cites W2075445339 @default.
• W2897449632 cites W2088690976 @default.
• W2897449632 cites W2093230554 @default.
• W2897449632 cites W2095618958 @default.
• W2897449632 cites W2113521542 @default.
• W2897449632 cites W2113523455 @default.
• W2897449632 cites W2116554142 @default.
• W2897449632 cites W2143138701 @default.
• W2897449632 cites W2143863753 @default.
• W2897449632 cites W2154130790 @default.
• W2897449632 cites W2166084034 @default.
• W2897449632 cites W2212695664 @default.
• W2897449632 cites W2274623524 @default.
• W2897449632 cites W2283037401 @default.
• W2897449632 cites W2323356988 @default.
• W2897449632 cites W2461029491 @default.
• W2897449632 cites W2550918296 @default.
• W2897449632 cites W2561330651 @default.
• W2897449632 cites W2598622710 @default.
• W2897449632 cites W2606022415 @default.
• W2897449632 cites W2609723037 @default.
• W2897449632 cites W2623290509 @default.
• W2897449632 cites W2624132157 @default.
• W2897449632 cites W2767428437 @default.
• W2897449632 cites W2768053061 @default.
• W2897449632 cites W2768078998 @default.
• W2897449632 cites W2770107124 @default.
• W2897449632 cites W2789453910 @default.
• W2897449632 cites W2792575938 @default.
• W2897449632 cites W2802509584 @default.
• W2897449632 doi "https://doi.org/10.1016/j.lungcan.2018.10.007" @default.
• W2897449632 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30429031" @default.
• W2897449632 hasPublicationYear "2018" @default.
• W2897449632 type Work @default.
• W2897449632 sameAs 2897449632 @default.
• W2897449632 citedByCount "43" @default.
• W2897449632 countsByYear W28974496322019 @default.
• W2897449632 countsByYear W28974496322020 @default.
• W2897449632 countsByYear W28974496322021 @default.
• W2897449632 countsByYear W28974496322022 @default.
• W2897449632 countsByYear W28974496322023 @default.
• W2897449632 crossrefType "journal-article" @default.
• W2897449632 hasAuthorship W2897449632A5000631349 @default.
• W2897449632 hasAuthorship W2897449632A5001634894 @default.
• W2897449632 hasAuthorship W2897449632A5014453416 @default.
• W2897449632 hasAuthorship W2897449632A5016678816 @default.
• W2897449632 hasAuthorship W2897449632A5021231793 @default.
• W2897449632 hasAuthorship W2897449632A5021282809 @default.
• W2897449632 hasAuthorship W2897449632A5022841989 @default.
• W2897449632 hasAuthorship W2897449632A5026742077 @default.
• W2897449632 hasAuthorship W2897449632A5034618792 @default.
• W2897449632 hasAuthorship W2897449632A5035063101 @default.
• W2897449632 hasAuthorship W2897449632A5038974897 @default.
• W2897449632 hasAuthorship W2897449632A5040362672 @default.
• W2897449632 hasAuthorship W2897449632A5044095460 @default.
• W2897449632 hasAuthorship W2897449632A5044612760 @default.
• W2897449632 hasAuthorship W2897449632A5044887899 @default.
• W2897449632 hasAuthorship W2897449632A5047294452 @default.

• next